Phathom Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
PHAT$5.33+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Years EndedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Product revenue, net | $682 | $— |
| Cost of revenue | 167 | — |
| Gross profit | 515 | — |
| Operating expenses: | ||
| Research and development (includes related party amounts of $760 and $2,123, respectively) | 49,899 | 71,441 |
| Selling, general and administrative (includes related party amounts of $55 and $0, respectively) | 117,928 | 100,999 |
| Total operating expenses | 167,827 | 172,440 |
| Loss from operations | (167,312) | (172,440) |
| Other income (expense): | ||
| Interest income | 7,876 | 2,132 |
| Interest expense | (41,968) | (27,305) |
| Other (expense), net | (188) | (110) |
| Total other expense | (34,280) | (25,283) |
| Net loss and comprehensive loss | $(201,592) | $(197,723) |
| Net loss per share, basic and diluted | $(3.93) | $(5.05) |
| Weighted-average shares of common stock outstanding, basic and diluted | 51,289,092 | 39,118,215 |
See accompanying notes
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.